First class new drug of Tianjin Pharmaceutical Research Institute
-
Last Update: 2016-02-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Zhifei zaxaban (ty602), a new drug independently developed and designed by Tianjin Pharmaceutical Research Institute, has been approved for clinical application It is the first anti coagulation drug independently developed and entered the clinical research stage in China Saban is a new generation of antithrombotic drugs, mainly used to prevent and treat venous thrombosis, pulmonary embolism, systemic embolism caused by atrial fibrillation and other acute and serious cardiovascular and cerebrovascular diseases At present, only a few of these drugs are on the market in the world, and all of them are in the hands of multinational companies Relying on the technical platforms of "National Key Laboratory of drug release technology and pharmacokinetics" and "Tianjin Key Laboratory of new drug design and discovery", Tianjin Pharmaceutical Research Institute has organized multi-disciplinary technical forces to develop zhifeisaban In the course of several years' development, it has been supported by national major new drug creation projects.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
